Category: Covid-19

Page 37«..1020..36373839..5060..»

NIH official finally admits taxpayers funded gain-of-function research in Wuhan after years of denials – New York Post

May 19, 2024

Politics

By Josh Christenson

Published May 16, 2024, 3:11 p.m. ET

Its about time!

At long last, National Institutes of Health (NIH) principal deputy director Lawrence Tabak admitted to Congress Thursday that US taxpayers funded gain-of-function research at the Wuhan Institute of Virology in China in the months and years before the COVID-19 pandemic.

Dr. Tabak, asked Rep. Debbie Lesko (R-Ariz.) of the Select Subcommittee on the Coronavirus Pandemic, did NIH fund gain-of-function research at the Wuhan Institute of Virology through [Manhattan-based nonprofit] EcoHealth [Alliance]?

It depends on your definition of gain-of-function research, Tabak answered. If youre speaking about the generic term, yes, we did.

The response comes after more than four years of evasions from federal public health officials including Tabak himself and former National Institute of Allergy and Infectious Diseases (NIAID) director Dr. Anthony Fauci about the controversial research practice that modifies viruses to make them more infectious.

Tabak added that this is research, the generic term [gain-of-function], is research that goes on in many, many labs around the country. It is not regulated. And the reason its not regulated is it poses no threat or harm to anybody.

Dr. Bryce Nickels, a professor of genetics at Rutgers University and co-founder of the pandemic oversight group Biosafety Now, told The Post the exchange was two people talking past each other.

Tabak was engaging in the usual obfuscation and semantic manipulation that is so frustrating and pointless, Nickels said, adding that the NIH bigwig was resisting accountability for risky research that can create pathogens of pandemic potential.

Instead of addressing this directly, Tabak launched into a useless response about how gain-of-function encompasses many types of experiments, he added.

In July 2023, the US Department of Health and Human Services (HHS) barred the Wuhan Institute of Virology from receiving federal grants for the next 10 years.

EcoHealth Alliance, whose mission statement declares it is working to prevent pandemics, had all of its grant funding pulled by HHS for the next three years on Tuesday.

EcoHealth Alliance president Dr. Peter Daszak, in a hearing earlier this month before the House Select Subcommittee on the Coronavirus Pandemic, testified that his organization never has and did not do gain-of-function research, by definition.

But that claim directly contradicted Daszaks private correspondence, including a 2016 email in which he celebrated the end of an Obama administration pause on gain-of-function research.

The EcoHealth head was also called out in sworn testimony to the COVID panel by Dr. Ralph Baric, a leading coronavirologist who initiated the research himself and declared it was absolutely gain-of-function.

In an October 2021 letter to Congress, Tabak had acknowledged NIH funded a limited experiment at the Wuhan Institute of Virology that tested whether spike proteins from naturally occurring bat coronaviruses circulating in China were capable of binding to the human ACE2 receptor in a mouse model.

He did not describe it as gain-of-function research but disclosed that EcoHealth failed to report the bat coronaviruses modified with SARS and MERS viruses had been made 10,000 times more infectious, in violation of its grant terms.

The NIH scrubbed its website of a longstanding definition for gain-of-function research the same day that the letter was sent.

Tabak also noted in his October 2021 letter that the sequences of the viruses are genetically very distant from COVID-19 but other grant proposals from EcoHealth have since drawn scrutiny for their genetic similarities.

Fauci has repeatedly denied that the Wuhan lab research involved gain-of-function experiments, clashing with Republicans in high-profile hearings and playing semantics with the term during a closed-door interview with the House COVID panel earlier this year.

He needs to define his definition of gain-of-function research, because as I have through this process in the last three years, read many, many published articles about gain-of-function research, or creation of a chimera, this is a new one, COVID subcommittee Chairman Brad Wenstrup (R-Ohio) said following Faucis grilling in January.

The ex-NIAID head and White House medical adviser under President Biden was escorted by Capitol Police and his attorneys to and from the committee room for his two days of interviews and repeatedly dodged The Posts questions about gain-of-function research and pandemic lockdown restrictions.

In 2021, Sen. Rand Paul (R-Ky.) held Faucis feet to the fire over the evasions in several hearings.

The NIH has not ever and does not now fund gain-of-function research in the Wuhan Institute of Virology, Fauci declared that May.

In another House hearing the same month, then-NIH director Dr. Francis Collins testified that researchers at the Wuhan lab were not approved by NIH for doing gain-of-function research.

We are, of course, not aware of other sources of funds or other activities they might have undertaken outside of what our approved grant allowed, Collins added cautiously at the time.

That ignorance about what experiments came about as a result of the NIH grants was underscored by Daszak during his COVID subcommittee hearing last week.

The EcoHealth leader acknowledged he had not askedlongtime collaborator and Wuhan Institute of Virology deputy director Shi Zhengli for any viral sequences since before the pandemic began.

In his own closed-door testimony to the House subcommittee released Thursday, Collins echoed Tabaks comments but went further by saying there is a generic description of gain-of-function which is utilized in scientific and public conversation, but is not appropriate to apply that to a circumstance where were talking about a potential pathogen.

We need to be highly cognizant of the risks of gain-of-function technology now that scientific capabilities exist for creating something in a lab that didnt exist 100 years ago, or even 50 years ago, Wenstrup told The Post following Thursdays hearing.

Drs. Fauci and Collins, over a decade ago, both conceded that there are risks associated with gain-of-function research.

EcoHealth received more than half a million dollars for its work with the Wuhan Institute of Virology as part of a grant of more than $4 million to study the emergence of bat coronaviruses between 2014 and 2024.

That grant was revoked in 2020, reinstated in 2023 and finally suspended and proposed for debarment this week.

The House subcommittee is still investigating whether COVID-19 accidentally leaked out of a lab in Wuhan, which has been described as the most likely cause of the pandemic by the FBI, US Energy Department, ex-Centers for Disease Control and Prevention (CDC) director Dr. Robert Redfield and former Director of National Intelligence John Ratcliffe.

Nickels also slammed Tabak Thursday for still claiming the evidence points to SARS-CoV-2 originating in a wild animal market in Wuhan.

No credible scientist still believes this. In fact, the wet market theory has even been refuted by the worlds leading coronavirus expert, Ralph Baric, in his testimony from January, Nickels said.

The Rutgers prof added that Thursdays hearing highlighted the lack of oversight for scientific research on pathogens that poses a threat to humans, making it up to the grantee to oversee themselves, as Wenstrup put it.

Its pure insanity to continue to delegate responsibly for risk/benefit analysis of research that poses an existential threat to humanity to the scientist that will perform the work and their institutions, Nickels claimed.

We just had a devastating pandemic likely caused by creation of a [Pathogen with Enhanced Pandemic Potential] in a lab, and yet scientists want the public to trust them that they can police themselves? he balked. Thats just total and complete nonsense.

Fauci is scheduled to answer questions about the gain-of-function research at the Wuhan lab and theories of the origin of the pandemic in a public subcommittee hearing set for June 3.

Load more...

https://nypost.com/2024/05/16/us-news/nih-director-admits-taxpayers-funded-gain-of-function-research-in-wuhan-four-years-after-covid-pandemic-began/?utm_source=url_sitebuttons&utm_medium=site%20buttons&utm_campaign=site%20buttons

Follow this link:

NIH official finally admits taxpayers funded gain-of-function research in Wuhan after years of denials - New York Post

Somber ceremony in Bissel Garden reflects on the impacts, lives lost during COVID-19 pandemic – Miami County Republic

May 19, 2024

State Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington D.C. West Virginia Wisconsin Wyoming Puerto Rico US Virgin Islands Armed Forces Americas Armed Forces Pacific Armed Forces Europe Northern Mariana Islands Marshall Islands American Samoa Federated States of Micronesia Guam Palau Alberta, Canada British Columbia, Canada Manitoba, Canada New Brunswick, Canada Newfoundland, Canada Nova Scotia, Canada Northwest Territories, Canada Nunavut, Canada Ontario, Canada Prince Edward Island, Canada Quebec, Canada Saskatchewan, Canada Yukon Territory, Canada

Zip Code

Country United States of America US Virgin Islands United States Minor Outlying Islands Canada Mexico, United Mexican States Bahamas, Commonwealth of the Cuba, Republic of Dominican Republic Haiti, Republic of Jamaica Afghanistan Albania, People's Socialist Republic of Algeria, People's Democratic Republic of American Samoa Andorra, Principality of Angola, Republic of Anguilla Antarctica (the territory South of 60 deg S) Antigua and Barbuda Argentina, Argentine Republic Armenia Aruba Australia, Commonwealth of Austria, Republic of Azerbaijan, Republic of Bahrain, Kingdom of Bangladesh, People's Republic of Barbados Belarus Belgium, Kingdom of Belize Benin, People's Republic of Bermuda Bhutan, Kingdom of Bolivia, Republic of Bosnia and Herzegovina Botswana, Republic of Bouvet Island (Bouvetoya) Brazil, Federative Republic of British Indian Ocean Territory (Chagos Archipelago) British Virgin Islands Brunei Darussalam Bulgaria, People's Republic of Burkina Faso Burundi, Republic of Cambodia, Kingdom of Cameroon, United Republic of Cape Verde, Republic of Cayman Islands Central African Republic Chad, Republic of Chile, Republic of China, People's Republic of Christmas Island Cocos (Keeling) Islands Colombia, Republic of Comoros, Union of the Congo, Democratic Republic of Congo, People's Republic of Cook Islands Costa Rica, Republic of Cote D'Ivoire, Ivory Coast, Republic of the Cyprus, Republic of Czech Republic Denmark, Kingdom of Djibouti, Republic of Dominica, Commonwealth of Ecuador, Republic of Egypt, Arab Republic of El Salvador, Republic of Equatorial Guinea, Republic of Eritrea Estonia Ethiopia Faeroe Islands Falkland Islands (Malvinas) Fiji, Republic of the Fiji Islands Finland, Republic of France, French Republic French Guiana French Polynesia French Southern Territories Gabon, Gabonese Republic Gambia, Republic of the Georgia Germany Ghana, Republic of Gibraltar Greece, Hellenic Republic Greenland Grenada Guadaloupe Guam Guatemala, Republic of Guinea, Revolutionary People's Rep'c of Guinea-Bissau, Republic of Guyana, Republic of Heard and McDonald Islands Holy See (Vatican City State) Honduras, Republic of Hong Kong, Special Administrative Region of China Hrvatska (Croatia) Hungary, Hungarian People's Republic Iceland, Republic of India, Republic of Indonesia, Republic of Iran, Islamic Republic of Iraq, Republic of Ireland Israel, State of Italy, Italian Republic Japan Jordan, Hashemite Kingdom of Kazakhstan, Republic of Kenya, Republic of Kiribati, Republic of Korea, Democratic People's Republic of Korea, Republic of Kuwait, State of Kyrgyz Republic Lao People's Democratic Republic Latvia Lebanon, Lebanese Republic Lesotho, Kingdom of Liberia, Republic of Libyan Arab Jamahiriya Liechtenstein, Principality of Lithuania Luxembourg, Grand Duchy of Macao, Special Administrative Region of China Macedonia, the former Yugoslav Republic of Madagascar, Republic of Malawi, Republic of Malaysia Maldives, Republic of Mali, Republic of Malta, Republic of Marshall Islands Martinique Mauritania, Islamic Republic of Mauritius Mayotte Micronesia, Federated States of Moldova, Republic of Monaco, Principality of Mongolia, Mongolian People's Republic Montserrat Morocco, Kingdom of Mozambique, People's Republic of Myanmar Namibia Nauru, Republic of Nepal, Kingdom of Netherlands Antilles Netherlands, Kingdom of the New Caledonia New Zealand Nicaragua, Republic of Niger, Republic of the Nigeria, Federal Republic of Niue, Republic of Norfolk Island Northern Mariana Islands Norway, Kingdom of Oman, Sultanate of Pakistan, Islamic Republic of Palau Palestinian Territory, Occupied Panama, Republic of Papua New Guinea Paraguay, Republic of Peru, Republic of Philippines, Republic of the Pitcairn Island Poland, Polish People's Republic Portugal, Portuguese Republic Puerto Rico Qatar, State of Reunion Romania, Socialist Republic of Russian Federation Rwanda, Rwandese Republic Samoa, Independent State of San Marino, Republic of Sao Tome and Principe, Democratic Republic of Saudi Arabia, Kingdom of Senegal, Republic of Serbia and Montenegro Seychelles, Republic of Sierra Leone, Republic of Singapore, Republic of Slovakia (Slovak Republic) Slovenia Solomon Islands Somalia, Somali Republic South Africa, Republic of South Georgia and the South Sandwich Islands Spain, Spanish State Sri Lanka, Democratic Socialist Republic of St. Helena St. Kitts and Nevis St. Lucia St. Pierre and Miquelon St. Vincent and the Grenadines Sudan, Democratic Republic of the Suriname, Republic of Svalbard & Jan Mayen Islands Swaziland, Kingdom of Sweden, Kingdom of Switzerland, Swiss Confederation Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand, Kingdom of Timor-Leste, Democratic Republic of Togo, Togolese Republic Tokelau (Tokelau Islands) Tonga, Kingdom of Trinidad and Tobago, Republic of Tunisia, Republic of Turkey, Republic of Turkmenistan Turks and Caicos Islands Tuvalu Uganda, Republic of Ukraine United Arab Emirates United Kingdom of Great Britain & N. Ireland Uruguay, Eastern Republic of Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam, Socialist Republic of Wallis and Futuna Islands Western Sahara Yemen Zambia, Republic of Zimbabwe

Read the rest here:

Somber ceremony in Bissel Garden reflects on the impacts, lives lost during COVID-19 pandemic - Miami County Republic

Federal Reserve Chair Jerome Powell working from home after testing positive for COVID-19 – Moneycontrol

May 19, 2024

Story continues below Advertisement

Federal Reserve Chair Jerome Powell has tested positive for COVID-19 and is experiencing related symptoms.

Powell tested positive late Thursday.

Story continues below Advertisement

Following Centers for Disease Control and Prevention guidance, he is staying away from others and working at home, a Fed spokesperson said.

Powell was a participant in a panel discussion in Amsterdam on Tuesday, where he said that the central bank is unlikely to raise its key interest rate in response to signs of stubborn inflation and underscored his view that price increases would soon start to cool again.

Powell, who was to deliver commencement remarks to Georgetown University Law Center in person, now plans to deliver his remarks via a prerecorded video, the spokesperson said.

Story continues below Advertisement

Powell previously tested positive for Covid in January 2023, and displayed mild symptoms, according to the Fed.

Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

View original post here:

Federal Reserve Chair Jerome Powell working from home after testing positive for COVID-19 - Moneycontrol

Global life expectancy rebounds after COVID-19 dip, could go up by 5 years by 2050 – Down To Earth Magazine

May 19, 2024

Life expectancy projected to rise by 0.16 years per year 2022-2050 notably lower than 0.27-year increase seen 1990-2019

While the COVID-19 pandemic caused a significant setback to global life expectancy, a new study suggests the decline may be reversing. Though life expectancy began to improve in 1990, a slump in growth rates was recorded in 2020 after COVID-19 struck, found the research published in The Lancet medical journal.

However, the numbers have since returned to or exceeded 2019 levels from 2022 to 2023.

The effects will likely be noticeable. Life expectancy is expected to increase by 0.16 years annually from 2022 to 2050, which is significantly less than the 0.27 years annual increase noted 1990 to 2019, according to the study.

From 2022 to 2050, life expectancy growth rates in high-income regions, North Africa, the Middle East, Southeast Asia, East Asia, and Oceania slowed down significantly compared to previous years.

Global and super-regional life expectancy 1990-2050

Forecasts based on reference scenario. Black vertical line indicates 2022. Source: The Lancet

In India, life expectancy was 60 for men and around 62 for women in 1990. It rose to 68 and 72 before dropping to 66 and 71 for men and women in 2021, respectively.

A Lancet study in April 2024 found that global life expectancy increased by 7.8 years from 1990 to 2019. However, from 2019 to 2021, COVID-19 and related deaths caused a 2.2-year decline. This decline was partially offset by reductions in other diseases, resulting in a net decrease of 1.6 years in global life expectancy.

But things are expected to change. By mid-century, global life expectancy is predicted to increase by nearly five years, from 73.6 years in 2022 to 78.1 years in 2050. Additionally, global healthy life expectancy (HALE) is expected to grow by 2.6 years, from 64.8 years in 2022 to 67.4 years in 2050.

In India, men and women are expected to live nearly seven years longer by 2050. The average lifespan is expected to be 76 and 80 in men and women, respectively.

Life expectancy and HALE in India, 1990-2050

The increase in life expectancy is likely due to public health measures that have prevented and improved survival rates for cardiovascular diseases, COVID-19 and various communicable, maternal, neonatal and nutritional diseases.

Across locations, the burden of disease will continue to shift from communicable, maternal, neonatal and nutritional diseases to non-communicable diseases (conditions that are not due to an infection. Examples include heart disease, cancer, chronic respiratory disease, and diabetes), the study read.

The researchers reached these findings by analysing estimates of years lived with disability, disability-adjusted life-years (DALY) and HALE for 204 countries and territories up to 2050. One DALY represents the loss of the equivalent of one year of full health.

The analysis also included measures of fatal disease burden mortality, years of life lost (YLL) and life expectancy. YLL measures years lost between the age at which a person dies and the number of years they could have potentially gone on to live, based on the current best life expectancy across the world.

The team used the 2021 Global Burden of Disease (GBD) estimates to project 359 causes of disease burden, both fatal and non-fatal, from 2022 to 2050 for 204 countries and territories. GBD is the most comprehensive assessment of health trends and conditions worldwide.

We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.

Visit link:

Global life expectancy rebounds after COVID-19 dip, could go up by 5 years by 2050 - Down To Earth Magazine

KP.2 is now the dominant COVID variant. Experts say US may see a summer increase in cases – ABC News

May 19, 2024

KP.2 currently makes up an estimated 28.2% of cases in the U.S., CDC data shows.

May 13, 2024, 5:07 PM ET

6 min read

For the last few months, JN.1 has been the dominant COVID-19 variant in the United States, making up the majority of cases. A new variant, however, has taken over and may lead to an increase in cases this summer.

KP.2, which is an offshoot of the omicron variant, currently accounts for an estimated 28.2% of COVID cases after making up just 1.4% of cases in mid March, according to data from the Centers for Disease and Prevention.

Over the past four years, the U.S. has seen summer waves of COVID and this summer may also bring a rise in cases, but not severe as in past seasons.

"We've had four consecutive increases of COVID in the summers in the last four years," Dr. Peter Chin-Hong, a professor of medicine and an infectious disease expert at the University of California, San Francisco (UCSF), told ABC News. "We expect an increase this summer too, but it probably won't be large and it probably won't be as profound as wintertime."

Chin-Hong said he would refer to the increase as more of a "swell" rather a "wave" or a "surge."

"Like when you're at the beach and you see the swell coming," he explained. "It's not like a tsunami, it's not like a huge wave crashing, it's just kind of like a little swell. But the swell does mean that some people are going to get sick."

Early data indicates KP.2 has more mutations to the spike protein than JN.1, which the virus uses to attach to -- and infect cells, which could potentially make KP.2 more infectious.

"The virus' capacity to evolve is anticipated, and it's something we've prepared for in our ongoing public health response," said Dr. John Brownstein, an epidemiologist and chief innovation officer at Boston Children's Hospital and an ABC News contributor. "Given the seasonal patterns observed with COVID-19, a slight uptick in cases could be anticipated this summer, making ongoing surveillance and vaccination efforts all the more essential."

Experts say there is no clear evidence that KP.2 -- which some scientists have nicknamed "FLiRT" on social media but is not an official name used by the CDC or the World Health Organization -- causes more severe illness or is more deadly than previous variants.

While more studies are needed to see if KP.2 is better at evading current vaccines than other variants, Chin-Hong said his experience at UCSF's hospital over the past few weeks seems to indicate that vaccines are continuing to provide good protection.

He said the one common factor among all the patients hospitalized at UCSF with severe COVID is that none of them received the updated COVID vaccine that rolled out in fall 2023.

"If you haven't done, go ahead and get it," Chin-Hong said.

He added that it's especially important for those who are immunocompromised or more susceptible to severe disease, such as being aged 65 and over, to get vaccinated.

COVID hospitalizations have not been increasing in the U.S., a milestone for the nation.

In late April, the latest week for which data is available, the U.S. hit 5,615 COVID weekly hospitalizations. By comparison, there were more than 150,000 weekly admissions at the peak of the omicron variant circulating in early 2022.

Experts say the U.S. is in a much better place to fight COVID than at the start of the pandemic and new variants are a reminder to remain vigilant, but not to panic.

"We have to remember this virus is now part of the respiratory mix we handle yearly just like influenza and, just like influenza, we try to stay ahead of the game to prepare for any possible surge or to understand how well the vaccines are matched," Brownstein said. "This is all bread-and-butter public health surveillance. It's important to stay up-to-date with vaccines and remain vigilant and stay home when sick."

Go here to read the rest:

KP.2 is now the dominant COVID variant. Experts say US may see a summer increase in cases - ABC News

New COVID-19 wave in Singapore, over 25k cases reported – Onmanorama

May 19, 2024

Singapore: Singapore is seeing a new COVID-19 wave as the authorities recorded more than 25,900 cases from May 5 to 11 even as Health Minister Ong Ye Kung on Saturday advised the wearing of masks again. We are at the beginning part of the wave where it is steadily rising, said Ong. So, I would say the wave should peak in the next two to four weeks, which means between mid- and end of June, The Straits Times newspaper quoted the minister as saying. The Ministry of Health (MOH) said the estimated number of COVID-19 cases in the week of May 5 to 11 rose to 25,900 cases, compared with 13,700 cases in the previous week.

The average daily COVID-19 hospitalisations rose to about 250 from 181 the week before. The average daily intensive care unit (ICU) cases remained low at three cases, compared with two cases in the previous week. The MOH said that to protect hospital bed capacity, public hospitals have been asked to reduce their non-urgent elective surgery cases and move suitable patients to transitional care facilities or back home through Mobile Inpatient Care@Home, an alternative inpatient care delivery model that offers clinically suitable patients the option of being hospitalised in their own homes instead of a hospital ward.

Ong urged those who are at greatest risk of severe disease, including individuals aged 60 years and above, medically vulnerable individuals and residents of aged care facilities, to receive an additional dose of the COVID-19 vaccine if they have not done so in the last 12 months. Ong said that if the number of COVID-19 cases doubles one time, Singapore will have 500 patients in its healthcare system, which is what Singapore can handle. However, if the number of cases doubles a second time, there will be 1,000 patients, and that will be a considerable burden on the hospital system, he pointed out.

One thousand beds is equivalent to one regional hospital, Ong said. So, I think the healthcare system has to brace ourselves for what is to come. There are no plans for any form of social restrictions or any other mandatory kind of measures for now, as COVID-19 is treated as an endemic disease in Singapore, he said, adding that imposing additional measures would be a last resort. Ong said that with Singapore being a transport and communications hub, it will be one of the cities to get a wave of COVID-19 earlier than others. So, COVID-19 is just something that we have to live with. Every year, we should expect one or two waves, he said.

Globally, the predominant COVID-19 variants are still JN.1 and its sub-lineages, including KP.1 and KP.2. Currently, KP.1 and KP.2 account for over two-thirds of cases in Singapore. As of May 3, the World Health Organisation has classified KP.2 as a variant under monitoring. There are currently no indications, globally or locally, that KP.1 and KP.2 are more transmissible or cause more severe disease than other circulating variants, the MOH said.

However, members of the public are urged to stay updated with vaccinations to protect themselves against current and emerging virus strains. The MOH said that to date, about 80 per cent of the local population have completed their initial or additional dose, but have not received a dose within the last year. The ministry added that since COVID-19 vaccination started in 2020 to 2021, the vaccines have consistently been proven to be safe and effective in protecting individuals from severe illness. Billions of doses have been administered globally, and safety monitoring internationally has shown that the vaccine is safe, it said.

There have also been no long-term safety concerns with COVID-19 vaccination, and adverse effects from vaccines, including the mRNA vaccines, have all been observed to occur shortly after vaccination, the ministry added.

Read more:

New COVID-19 wave in Singapore, over 25k cases reported - Onmanorama

US taxpayers money used for controversial virus research in Wuhan – The Times of India

May 19, 2024

NEW DELHI: National Institutes of Health (NIH) principal deputy director Lawrence Tabak admitted to Congress on Thursday that US taxpayers funded gain-of-function research at the Wuhan Institute of Virology in China prior to the Covid-19 pandemic. Rep Debbie Lesko (R-Ariz) of the select subcommittee on the coronavirus pandemic questioned Dr Tabak, asking, Did NIH fund gain-of-function research at the Wuhan Institute of Virology through [Manhattan-based nonprofit] EcoHealth [Alliance]? Tabak replied, If youre speaking about the generic term, yes, we did. This admission comes after more than four years of evasions from federal public health officials, including Tabak himself and former National Institute of Allergy and Infectious Diseases (NIAID) director Dr Anthony Fauci, regarding the controversial research practice that modifies viruses to make them more infectious. Tabak clarified that this type of research is widespread and poses no threat or harm, which is why it is not regulated, a New York Post report said. Dr Bryce Nickels, a genetics professor at Rutgers University, criticized Tabak's response, describing it as obfuscation and semantic manipulation. He accused the NIH official of resisting accountability for risky research that could create pathogens of pandemic potential. In July 2023, the US Department of Health and Human Services (HHS) barred the Wuhan Institute of Virology from receiving federal grants for the next 10 years. Additionally, EcoHealth Alliance, which had its funding pulled by HHS for the next three years, has faced scrutiny for its involvement in the research. Tabak previously acknowledged in an October 2021 letter to Congress that NIH funded a "limited experiment" at the Wuhan Institute of Virology, which tested whether spike proteins from naturally occurring bat coronaviruses could bind to the human ACE2 receptor in a mouse model. This experiment, which involved modifying bat coronaviruses with SARS and MERS viruses, was not described as gain-of-function research, despite EcoHealth's failure to report that the modified viruses became 10,000 times more infectious, violating grant terms. Despite repeated denials by Dr Anthony Fauci, Republicans have consistently challenged the NIH's involvement in gain-of-function research. Sen Rand Paul (R-Ky) notably grilled Fauci in several hearings, demanding clarity on the NIH's funding practices. The House subcommittee continues to investigate whether Covid-19 accidentally leaked from a lab in Wuhan, which several US intelligence agencies and experts have suggested as the most likely cause of the pandemic. Dr. Robert Redfield, former director of the Centers for Disease Control and Prevention (CDC), and former Director of National Intelligence John Ratcliffe have both supported this theory. Nickels concluded that the hearing underscored the lack of oversight for scientific research on pathogens, highlighting the need for stricter controls and accountability to prevent future pandemics. Dr Fauci is scheduled to testify about gain-of-function research and the origins of the pandemic in a public subcommittee hearing on June 3.

Go here to read the rest:

US taxpayers money used for controversial virus research in Wuhan - The Times of India

New COVID Variant Could Cause Uptick In Cases In MA: What To Know – Patch

May 19, 2024

The nickname of the new variant, FLiRT, references the technical names of its mutations, F4561 and R346T, and are part of SARS-CoV-2s Omicron lineage. (Renee Schiavone/Patch)

MASSACHUSETTS The new KP.2 variant nicknamed FLiRT could cause an uptick in COVID-19 cases in Massachusetts and around the country this summer, disease experts are warning.

Centers for Disease Control and Prevention data released Friday showed the KP.2 variant represents 28 percent of new COVID infections from April 14-27, up from just 6 percent.

Subscribe

The variants collectively known as FLiRT include KP.2 and another variant, KP.1.1, both of which are descendants of JN.1. They share the same mutation, changes in the spike protein that allows the virus to colonize in the body and make people sick

In Region 1, the region including Massachusetts, the KP.2 variant was responsible for 24.3 percent of COVID cases from April 27-May 5.

The nickname FLiRT references the technical names of its mutations, F4561 and R346T, and are part of SARS-CoV-2s Omicron lineage.

The CDC said there is no indication people will get any sicker with KP.2 than with other strains. The KP.2 variant overtook JN.1 as the dominant strain. Symptoms are similar, although the CDC cautioned they may vary among people and may change with new variants.

Laboratory research from Japan, which has not yet been peer-reviewed and was published as a preprint, suggests the mutations may be able to bypass vaccines.

It looks like those additional mutations make it more immune evasive, so its not a surprise that it would then dominate, Dr. Dan Barouch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston, told NBC News.

According to the research from Japan, the KP.2 variant may be less efficient than its predecessors at infecting cells. The current vaccines should provide some protection against KP.2, according to experts.

However, vaccine coverage is waning nationwide, with only 22.6 percent of U.S. adults currently protected by the updated 2023-24 COVID vaccine rolled out in September 2023, according to CDC data. Vaccine protection increased by age groups, with the highest coverage among adults 75 and older.

Hospitalizations for COVID-19 reached record lows in April, and the CDC no longer requires hospitals to report admissions numbers. Experts say that while serious cases requiring hospitalization may increase this summer, as they have every summer since the pandemic began in 2020, the rise wont be nearly as dramatic.

The CDC updated its COVID-19 guidance in March, ending its recommendation that people who test positive for the virus isolate for five days. However, the agency still recommends that people take precautions to prevent the spread of COVID, or any other common respiratory disease, including staying home when theyre sick, staying up-to-date on vaccines and properly washing their hands.

View original post here:

New COVID Variant Could Cause Uptick In Cases In MA: What To Know - Patch

Mental Health Claims Increased 56% from 2019 to 2022 – Behavioral Health Business

May 19, 2024

New research shows mental health insurance claims have continued to rise after the peak impact of the COVID-19 pandemic.

Mental health claims soared by 83% from 2019 to 2023 and continued to rise post-pandemic, increasing 11% from 2022 to 2023, according to a report from LexisNexis Risk Solutions.

The demand for virtual mental health services skyrocketed even more dramatically during this period, jumping 9,500%, though virtual claims are now starting to level off.

Mental health claims continue to rise, indicating a growing demand and utilization of mental health care, despite ongoing provider and medication shortages, Adam Mariano, president and general manager of health care at LexisNexis Risk Solutions, said in a statement.

The sharp increase in telehealth visits caused by the pandemic has begun to level off, but the number of virtual mental health claims remains high. Overall virtual mental health claims increased by 3% from 2022 to 2023, although these visits declined by 14% among children.

The shift away from virtual and back to in-office care is most evident among children and teens under 18, the reports authors wrote. This is a clear indication that healthcare organizations should be prepared with adequate resources for both care venues, with a particular focus on engaging with the younger generation in person.

Research has shown telehealth mental health visits are as beneficial as in-person visits. Still, some COVID-era flexibilities that allow mental health providers to offer telehealth may expire at the end of 2024 unless the federal government takes action.

In-office claims, which dropped a dramatic 46% from 2019 to 2020, are now rebounding, increasing 59% from 2021 to 2023. In-person claims are now only 10% lower than where they stood pre-pandemic in 2019.

Within rising mental health claims, some conditions saw more claims increases than others, with stress, developmental disorders, anxiety and depression experiencing the highest increases.

Stress-related claims increased by 86% from 2019 to 2023, followed by developmental disorder claims, which jumped by 75%, anxiety claims, which increased by 72% and depression-related claims, which climbed by 52%.

ADHD claims surged dramatically among adults in the last five years, with 101% more claims among people ages 18 to 44.

There was a sharp rise in insurance claims related to gender identity and eating disorders among minors in the past five years. Compared to 2019 levels, claims for gender identity issues among patients under 18 increased by 152%, while claims for eating disorders in the same age group went up by 131%.

Other mental health condition claims also jumped among minors. Claims related to phobic disorders saw a 98% increase compared to 2019. Anxiety disorder claims went up by 82%, and those for developmental disorders increased by 77%.

Editors note: This article has been updated to reflect the most recently available data. It originally included data published in 2023.

Original post:

Mental Health Claims Increased 56% from 2019 to 2022 - Behavioral Health Business

Pre-vaccine COVID-19: US study reveals hospitalization rate of 5.7% and fatality rate of 1.7% – News-Medical.Net

May 19, 2024

In a recent study published in the journal Emerging Infectious Diseases, researchers estimated hospitalization and mortality rates in people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States (US) in the pre-vaccination period.

The coronavirus disease 2019 (COVID-19) pandemic caused more than 20 million cases, 480,000 hospitalizations, and 350,000 deaths in the US until December 2020. COVID-19 case detection was considerably affected by commercial testing and at-home diagnostic tests beginning in mid-December 2020.

Further, the development of vaccines after mid-December 2020 has substantially reduced hospitalization and mortality rates. Studies have reported higher case fatality rates associated with specific individual-level, country-level, and clinical characteristics. Moreover, precise hospitalization and mortality estimates in SARS-CoV-2-nave populations are limited.

Study: Estimates of SARS-CoV-2 Hospitalization and Fatality Rates in the Prevaccination Period, United States. Image Credit:Photo Spirit / Shutterstock

In the present study, researchers estimated COVID-19 hospitalization and mortality rates before vaccines were available in the US. The Centers for Disease Control and Prevention (CDC) received COVID-19 case reports from epidemiologists from 56 US jurisdictions (50 states, the District of Columbia, the US Virgin Islands, Puerto Rico, Guam, Northern Mariana Islands, and New York City).

Datasets of hospitalization and mortality were generated for jurisdictions with more than 80% of cases having non-missing CDC hospitalization and death queries for illnesses between May 1 and December 1, 2020. The team estimated COVID-19 case hospitalization and fatality rates by age group, sex, race/ethnicity, hospitalization, intensive care unit (ICU) admission, and symptom status. Demographic characteristics of cases were described.

Overall, more than 10.33 million COVID-19 cases were reported to the CDC during the study period. Of these, 58.8% and 63.5% had valid, non-missing data on hospitalization and death, respectively. Accordingly, hospitalization and death datasets included over 2.47 million and 4.7 million cases from 21 and 22 jurisdictions, respectively.

Upper and lower estimates of case-hospitalization (gray) and case-fatality (black) rates by age group of patients with SARS-CoV-2 infection, United States, 2020.For case-hospitalization, lower bound was calculated by including cases with unknown hospitalization information as not hospitalized and upper bound by excluding cases with unknown hospitalization information. For case-fatality, lower bound was calculated by including cases with unknown death status as alive and upper bound by excluding cases with unknown death status information. Reports in which no response was provided about death or hospitalization were excluded from the respective rate calculation. Inset graph provides greater detail for younger age groups by using smaller y-axis values.

The resultant study populations closely matched the 2019 US Census population distribution by age group and sex, albeit were variable by race/ethnicity. The overall COVID-19 case hospitalization rate was 5.7%. It was < 8.3% in all age groups up to 64 years, viz., 5% in infants (< 1 year), 1.2% in those aged 14, and 0.6% in the 514 age group.

The hospitalization rate increased steadily in individuals aged 15 or older. It was 16.3% in those aged 6574 and 25.9% in 7584 and > 85 age groups. The hospitalization rate was 5.2% in females and 6.2% in males. Females had lower rates in all age groups except those aged 1534. Further, the hospitalization rate was 3.3% among asymptomatic cases and 6.3% among symptomatic individuals.

In addition, non-Hispanic African American or Black individuals had the highest hospitalization rate (11.4%). Consistently, it was the highest in non-Hispanic African American or Black individuals (14%) after adjusting for age, followed by those who were Asian or Pacific Islander (11%). Non-Hispanic White people showed the lowest hospitalization rate (6.8%).

The case fatality rate was 1.7% overall. It was below 1.6% in people aged up to 64 years, with 0.05% in infants, 0.01% in 14 and 514 age groups, 4.7% in people aged 6574, 12% in the 7584 age group, and 23.6% in those aged 85 or older. The fatality rate was 1.5% in females and 1.9% in males. Lower fatality rates were observed in all age groups except infants in females.

The fatality rate was the same (1.7%) in asymptomatic and symptomatic subjects. It was the highest in people who were Asian or Pacific Islander (3%), followed by non-Hispanic African American or Black individuals (2.7%). All racial/ethnic groups except non-Hispanic whites had higher fatality rates after adjusting for age. The fatality rates in non-hospitalized, hospitalized, and ICU patients were 0.6%, 17.6%, and 44.2%, respectively.

In sum, the study presented COVID-19 case hospitalization and fatality rates before vaccination or at-home testing was available in the US. Age was the primary driver of hospitalization and mortality. Rates exhibited a U-shaped curve, i.e., lower in infants (under one year), lowest in children aged 514, and highest among adults over 65. Overall, the findings underscore the severity of infections early in the pandemic and suggest that appropriate measures in historically underserved racial/ethnic groups and high-risk groups will be paramount.

Journal reference:

See the original post here:

Pre-vaccine COVID-19: US study reveals hospitalization rate of 5.7% and fatality rate of 1.7% - News-Medical.Net

Page 37«..1020..36373839..5060..»